美国食品和药物管理局批准使用LEQEMBI治疗罕见的阿尔茨海默病,旨在改善患者的治疗依从性. FDA approves LEQEMBI for less frequent Alzheimer's treatment, aiming to improve patient adherence.

食品和药物管理局批准了LEQEMBI(Lecanemab-irmb)为治疗美国早期阿尔茨海默氏病每四个星期一次的静脉维持剂量。 The FDA has approved LEQEMBI® (lecanemab-irmb) for once-every-four-weeks intravenous maintenance dosing to treat early Alzheimer's disease in the U.S. 这种从更频繁使用剂量的过渡旨在改善病人的坚持和延长治疗的好处,从而可能帮助病人保持更长时间的认知能力。 This transition from more frequent dosing aims to improve patient adherence and prolong therapy benefits, potentially helping patients maintain cognitive abilities longer. 该药物针对大脑中的氨基甲状腺-贝塔斑块,已在几个国家得到批准。 The drug, which targets amyloid-beta plaques in the brain, is already approved in several countries.